3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
3
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
5
Insulin Resistance
3
Diabetes Mellitus, Type 2
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Diabetes Mellitus
2
Carotid Intimal Medial Thickness 1
2
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Pharmacokinetics of MDV3100
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Memory Disorders
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Chronic-Phase
1
Inflammation
1
Head and Neck Neoplasms
1
Glioblastoma
1
Cognitive Dysfunction
1
Carcinoma, Squamous Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Docetaxel
158
Prednisone
131
Leuprolide
95
bicalutamide
86
enzalutamide
83
Radiotherapy
80
Goserelin
80
Abiraterone Acetate
76
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
54
Magnetic Resonance Spectroscopy
46
Zoledronic Acid
44
gallium 68 PSMA-11
37
Flutamide
34
abiraterone
32
Estramustine
32
radium Ra 223 dichloride
30
apalutamide
27
Surveys and Questionnaires
26
Gonadotropin-Releasing Hormone
26
Androgen Antagonists
25
cabazitaxel
24
Radiosurgery
24
Dutasteride
22
sipuleucel-T
21
Prednisolone
21
Triptorelin Pamoate
20
Paclitaxel
20
luprolide acetate gel depot
19
Radiation
19
Exercise
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Prostatic Neoplasms
×
Pioglitazone
×
Clear all
NCT00427999
2016-11-21
INV342
Novartis
Phase 2
Completed
67 enrolled
6 charts